Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 Jun 24

PMID 35742495

Authors

Sidsel Dan Hull

Marianne Welzel Andersen

Jessica Bengtsson

Nils Skovgaard

Marie Balslev Backe

Michael Lynge Pedersen

Affiliations

Soon will be listed here.

Abstract

This study estimates the age- and sex-specific prevalence of patients receiving urate-lowering therapy (ULT) in Greenland and compares the results with estimates in Denmark. Characteristics of patients receiving ULT in Greenland were compared to age- and sex-matched controls. The study was designed as a cross-sectional case−control study based on nationwide data from medical and population registers in Greenland and Denmark. The prevalence of patients receiving ULT was significantly lower in Greenland (0.55%) compared to Denmark (1.40%) (p < 0.001). In both countries, the prevalence increased with age and was higher among men compared to women. In Greenland, patients receiving ULT were more often overweight, and more frequently received blood glucose-, lipid-, and blood pressure-lowering medicine including diuretics compared to age- and sex-matched controls. The prevalence of patients receiving ULT was significantly lower in Greenland compared to Denmark. Common life-style related risk factors for hyperuricemia and gout were observed frequently among ULT-treated patients compared to controls. Along with an increasing prevalence of lifestyle-related diseases in Greenland, the prevalence of patients receiving ULT may increase in the years to come. More focus on detection and management of hyperuricemia and gout in Greenland is warranted to improve quality of health care.

Citing Articles

Burden of selected chronic non-communicable diseases in a primary healthcare setting in Nuuk, Greenland, compared to a Danish suburb.

Backe M, Kallestrup P, Rasmussen K, Jorgensen M, Pedersen M Scand J Prim Health Care. 2024; 42(3):435-441.

PMID: 38578458 PMC: 11332282. DOI: 10.1080/02813432.2024.2334746.

References

Zobbe K, Prieto-Alhambra D, Cordtz R, Hojgaard P, Hindrup J, Kristensen L . Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology (Oxford). 2018; 58(5):836-839. DOI: 10.1093/rheumatology/key390. View

Horsburgh S, Norris P, Becket G, Arroll B, Crampton P, Cumming J . Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int. 2014; 34(7):963-70. DOI: 10.1007/s00296-013-2935-5. View

Jorgensen M, Bjeregaard P, Borch-Johnsen K . Diabetes and impaired glucose tolerance among the inuit population of Greenland. Diabetes Care. 2002; 25(10):1766-71. DOI: 10.2337/diacare.25.10.1766. View

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J . 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2019; 79(1):31-38. DOI: 10.1136/annrheumdis-2019-215315. View

Choi H, Atkinson K, Karlson E, Curhan G . Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005; 165(7):742-8. DOI: 10.1001/archinte.165.7.742. View

Backe M, Pedersen M . Prevalence, incidence, mortality, and quality of care of diagnosed diabetes in Greenland. Diabetes Res Clin Pract. 2019; 160:107991. DOI: 10.1016/j.diabres.2019.107991. View

Kuo C, Grainge M, Zhang W, Doherty M . Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11):649-62. DOI: 10.1038/nrrheum.2015.91. View

Meklenborg I, Pedersen M, Bonefeld-Jorgensen E . Prevalence of patients treated with anti-diabetic medicine in Greenland and Denmark. A cross-sectional register study. Int J Circumpolar Health. 2018; 77(1):1542930. PMC: 6282445. DOI: 10.1080/22423982.2018.1542930. View

Evans P, Prior J, Belcher J, Mallen C, Hay C, Roddy E . Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. Arthritis Res Ther. 2018; 20(1):136. PMC: 6034249. DOI: 10.1186/s13075-018-1612-1. View

10.

Kuo C, Grainge M, Mallen C, Zhang W, Doherty M . Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2014; 75(1):210-7. PMC: 4717388. DOI: 10.1136/annrheumdis-2014-206410. View

11.

Kiadaliri A, Uhlig T, Englund M . Burden of gout in the Nordic region, 1990-2015: findings from the Global Burden of Disease Study 2015. Scand J Rheumatol. 2018; 47(5):410-417. DOI: 10.1080/03009742.2017.1405461. View

12.

Harrold L, Saag K, Yood R, Mikuls T, Andrade S, Fouayzi H . Validity of gout diagnoses in administrative data. Arthritis Rheum. 2007; 57(1):103-8. DOI: 10.1002/art.22474. View

13.

Jorgensen M, Borch-Johnsen K, Witte D, Bjerregaard P . Diabetes in Greenland and its relationship with urbanization. Diabet Med. 2011; 29(6):755-60. DOI: 10.1111/j.1464-5491.2011.03527.x. View

14.

Dehlin M, Jacobsson L, Roddy E . Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16(7):380-390. DOI: 10.1038/s41584-020-0441-1. View

15.

Pedersen M . Diabetes care in the dispersed population of Greenland. A new model based on continued monitoring, analysis and adjustment of initiatives taken. Int J Circumpolar Health. 2020; 78(sup1):1709257. PMC: 7034430. DOI: 10.1080/22423982.2019.1709257. View

16.

Winder M, Owczarek A, Mossakowska M, Broczek K, Grodzicki T, Wierucki L . Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles-Results from a Population-Based PolSenior Study. Int J Environ Res Public Health. 2021; 18(2). PMC: 7825523. DOI: 10.3390/ijerph18020387. View

17.

Zhu Y, Pandya B, Choi H . Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125(7):679-687.e1. DOI: 10.1016/j.amjmed.2011.09.033. View

18.

Sampson A, Singer R, Walters G . Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 2017; 10:CD009460. PMC: 6485406. DOI: 10.1002/14651858.CD009460.pub2. View

19.

Ingemann T, Backe M, Bonefeld-Jorgensen E, Skovgaard N, Pedersen M . Prevalence of patients treated with antidepressant medicine in Greenland and Denmark: a cross-sectional study. Int J Circumpolar Health. 2021; 80(1):1912540. PMC: 8078927. DOI: 10.1080/22423982.2021.1912540. View

20.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J . 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707. View